Vaxcyte Inc
PCVX
Company Profile
Business description
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Contact
825 Industrial Road
Suite 300
San CarlosCA94070
USAT: +1 650 837-0111
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
414
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,244.80 | 11.80 | -0.13% |
| CAC 40 | 8,060.13 | 85.28 | 1.07% |
| DAX 40 | 24,597.13 | 211.35 | 0.87% |
| Dow JONES (US) | 46,609.30 | 6.32 | 0.01% |
| FTSE 100 | 9,548.87 | 65.29 | 0.69% |
| HKSE | 26,829.46 | 128.31 | -0.48% |
| NASDAQ | 22,998.33 | 209.97 | 0.92% |
| Nikkei 225 | 47,734.99 | 215.89 | -0.45% |
| NZX 50 Index | 13,568.48 | 37.19 | 0.27% |
| S&P 500 | 6,748.19 | 33.60 | 0.50% |
| S&P/ASX 200 | 8,947.60 | 10.80 | -0.12% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |